| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Furaltadone Hydrochloride targets bacterial enzymes and cellular processes through its nitrofuran moiety. Nitrofurans are prodrugs that are activated by bacterial nitroreductases to generate reactive intermediates. These intermediates damage bacterial DNA, proteins, and other macromolecules, leading to bacterial cell death. Its antibacterial activity is broad-spectrum, covering both Gram-positive and Gram-negative organisms.
|
|---|---|
| ln Vitro |
In vitro, furaltadone hydrochloride exhibits antibacterial activity against various bacterial pathogens. It has in vitro staphylococcal activity. The compound's efficacy against Salmonella enterica has been demonstrated in vitro. Its activity as a nitrofuran antibiotic is characterized by its ability to inhibit bacterial growth in culture. Its antibacterial spectrum includes both Gram-positive and Gram-negative organisms.
|
| ln Vivo |
In vivo, furaltadone hydrochloride is effective against bacterial infections in birds when added to feed or drinking water. It has a distinct curative effect in the treatment of coccidiosis. The compound is used in veterinary medicine to treat bacterial infections in poultry and other animals. Its in vivo efficacy has been demonstrated in various animal models of infection.
|
| Enzyme Assay |
In vitro enzyme assays for furaltadone hydrochloride are not typically performed, as it is a prodrug that is activated by bacterial nitroreductases. Its antibacterial activity is assessed using standard broth microdilution or agar dilution methods against various bacterial strains. The minimum inhibitory concentration (MIC) is determined for each bacterial isolate. Its activity against Salmonella enterica and Staphylococcus aureus has been characterized.
|
| Cell Assay |
In vitro cell-based assays for furaltadone hydrochloride involve treating bacterial cultures with the compound to assess its antibacterial activity. Bacteria are cultured in the presence of varying concentrations of the compound, and growth inhibition is measured by optical density or colony counting. The compound's effects on bacterial cell viability and morphology can also be assessed. Its activity against various bacterial strains has been characterized.
|
| Animal Protocol |
In vivo animal experiments for furaltadone hydrochloride have been conducted in birds, where it is added to feed or drinking water to treat bacterial infections. Its efficacy in treating coccidiosis has been demonstrated. Efficacy endpoints include reduction in mortality, improvement in clinical signs, and reduction in bacterial load. The compound is used in veterinary medicine for the treatment of bacterial infections.
|
| ADME/Pharmacokinetics |
Furaltadone Hydrochloride has a molecular weight of 360.75 and a molecular formula of C13H17ClN4O6. It is a yellow crystalline powder with a bitter taste. The compound is a nitrofuran antibiotic. It is typically stored under recommended conditions for pharmaceutical compounds. Its physical and chemical properties are consistent with other nitrofuran derivatives.
|
| Toxicity/Toxicokinetics |
Furaltadone Hydrochloride is a nitrofuran antibiotic with potential toxicity concerns. Nitrofurans are known to have genotoxic and carcinogenic properties, and their use in food-producing animals is regulated in many countries. The compound is a metabolite of nitrofuran found in milk. Proper safety precautions should be taken when handling this compound. Its use is restricted in many jurisdictions.
|
| Additional Infomation |
Furaltadone Hydrochloride is a nitrofuran antibiotic with antibacterial activity. It is effective against Salmonella enterica infections and has in vitro staphylococcal activity. The compound has a distinct curative effect in the treatment of coccidiosis. It is used in veterinary medicine for bacterial infections in birds. Furaltadone HCl is a metabolite of nitrofuran found in milk.
|
| Molecular Formula |
C13H16N4O6.HCL
|
|---|---|
| Molecular Weight |
360.75
|
| Exact Mass |
360.083
|
| CAS # |
3759-92-0
|
| Related CAS # |
Furaltadone;139-91-3;Furaltadone L-tartrate;14343-71-6
|
| PubChem CID |
5393144
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
461.4ºC at 760 mmHg
|
| Melting Point |
>300?C (dec.)
|
| Flash Point |
232.8ºC
|
| Vapour Pressure |
1.08E-08mmHg at 25°C
|
| LogP |
1.875
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
476
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C1OC(CN2CCOCC2)CN1/N=C/C3=CC=C([N+]([O-])=O)O3.[H]Cl
|
| InChi Key |
PPSVFZXMDMUIGB-FJUODKGNSA-N
|
| InChi Code |
InChI=1S/C13H16N4O6.ClH/c18-13-16(14-7-10-1-2-12(22-10)17(19)20)9-11(23-13)8-15-3-5-21-6-4-15;/h1-2,7,11H,3-6,8-9H2;1H/b14-7+;
|
| Chemical Name |
5-(morpholin-4-ylmethyl)-3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 25 mg/mL (~69.30 mM)
DMSO : ~16.67 mg/mL (~46.21 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7720 mL | 13.8600 mL | 27.7200 mL | |
| 5 mM | 0.5544 mL | 2.7720 mL | 5.5440 mL | |
| 10 mM | 0.2772 mL | 1.3860 mL | 2.7720 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
